Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 26:14:1125246.
doi: 10.3389/fimmu.2023.1125246. eCollection 2023.

The development of COVID-19 treatment

Yongliang Yuan  1 , Baihai Jiao  2 , Lili Qu  3 , Duomeng Yang  3 , Ruijuan Liu  1
Affiliations
Review

The development of COVID-19 treatment

Yongliang Yuan et al. Front Immunol. .

Abstract

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest worldwide public health threat of this century. Recent studies have unraveled numerous mysteries of SARS-CoV-2 pathogenesis and thus largely improved the studies of COVID-19 vaccines and therapeutic strategies. However, important questions remain regarding its therapy. In this review, the recent research advances on COVID-19 mechanism are quickly summarized. We mainly discuss current therapy strategies for COVID-19, with an emphasis on antiviral agents, neutralizing antibody therapies, Janus kinase inhibitors, and steroids. When necessary, specific mechanisms and the history of therapy are present, and representative strategies are described in detail. Finally, we discuss key outstanding questions regarding future directions of the development of COVID-19 treatment.

Keywords: COVID-19; Janus kinase inhibitors; antiviral agents; neutralizing antibody therapy; treatments.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Category of COVID-19 treatments. On the basis of their targets, the treatments can be divided into two big categories: antiviral agents and therapies targeting host.
Figure 2
Figure 2
Comparison between different treatments. The advantages and disadvantages of each treatment are summarized on the basis of whether they will be efficient to variants, have side effects, or effect fast.
See this image and copyright information in PMC

References

    1. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta BioMed (2020) 91(1):157–60. doi: 10.23750/abm.v91i1.9397 - DOI - PMC - PubMed
    1. Abbasi J. Fourth COVID-19 vaccine dose increases low antibodies. JAMA (2022) 327(6):517. doi: 10.1001/jama.2022.0727 - DOI - PubMed
    1. Altmann DM, Boyton RJ. COVID-19 vaccination: The road ahead. Science (2022) 375(6585):1127–32. doi: 10.1126/science.abn1755 - DOI - PubMed
    1. Dube E, MacDonald NE. COVID-19 vaccine hesitancy. Nat Rev Nephrol (2022) 18(7):409–10. doi: 10.1038/s41581-022-00571-2 - DOI - PMC - PubMed
    1. Niknam Z, Golchin A, Danesh Pouya F, Nemati M, Rezaei-Tavirani M. Potential therapeutic options for COVID-19: an update on current evidence. Eur J Med Res (2022) 27(1):6. doi: 10.1186/s40001-021-00626-3 - DOI - PMC - PubMed

Publication types